Teladoc Health (TDOC) – Analysts’ Recent Ratings Updates

Teladoc Health (NYSE: TDOC) recently received a number of ratings updates from brokerages and research firms:

• 12/22/2025 – Teladoc Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Teladoc Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/9/2025 – Teladoc Health is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $8.50 price target on the stock.
• 12/8/2025 – Teladoc Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Teladoc Health was upgraded by analysts at Barclays PLC to a “hold” rating.
• 12/1/2025 – Teladoc Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Teladoc Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Teladoc Health had its price target lowered by analysts at Bank of America Corporation from $9.00 to $8.00. They now have a “neutral” rating on the stock.
• 11/13/2025 – Teladoc Health is now covered by analysts at BMO Capital Markets. They set a “market perform” rating and a $8.00 price target on the stock.
• 11/10/2025 – Teladoc Health was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 10/30/2025 – Teladoc Health had its price target lowered by analysts at Evercore ISI from $9.00 to $8.00. They now have an “in-line” rating on the stock.

Insider Activity

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carlos Nueno sold 3,897 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the sale, the insider directly owned 27,175 shares of the company’s stock, valued at approximately $203,540.75. This represents a 12.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is currently owned by insiders.

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.